Cellanome vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellanome is building a multi-omics platform combining genome sequencing, microfluidics, and integrated sensors to measure biological data at single-cell resolution; raised $100M Series A in 2023;
About
Cellanome is a biotechnology tools company founded in 2021 and headquartered in Menlo Park, California. The company is developing a next-generation multi-omics platform designed to simultaneously measure multiple layers of biological information — including genomics, transcriptomics, and proteomics — at single-cell resolution and at unprecedented scale. Its platform integrates genome sequencing, microfluidics, and proprietary integrated sensors to capture a more complete molecular portrait of individual cells than any existing single-omics technology can achieve alone.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Cellanome vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.